Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
10.3971/j.issn.1000-8578.2021.21.0357
- VernacularTitle:外周血生物标志物与PD-1/PD-L1抑制剂治疗肺癌疗效的相关性
- Author:
Ping KE
1
;
Bo JIANG
;
Wenjie HE
;
Changling TU
;
Jun NIE
;
Ying ZHU
;
Qing YIN
;
Ruizhu SUN
Author Information
1. Cadre Medical Department, The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China
- Publication Type:Research Article
- Keywords:
Lung cancer;
Immune checkpoint inhibitors;
Peripheral blood markers;
Efficacy;
Survival
- From:
Cancer Research on Prevention and Treatment
2021;48(11):1006-1011
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the predictive and guiding significance of peripheral blood biomarkers on the therapeutic effects of PD-1/PD-L1 inhibitor treatment on lung cancer patients. Methods We collected the data of 200 lung cancer patients treated with PD-1/PD-L1 inhibitors treatment, including clinical indicators, peripheral blood indicators, efficacy indicators and survival indicators. Results The DCR of patients with non-hepatic metastasis, immune combined chemotherapy, NLR≤2.81 and LDH≤202.5 u/L was higher (P < 0.05). The AUC value of NLR combined with LDH predicting DCR was 0.698 (P < 0.05). Univariate analysis showed that non-hepatic metastasis, first-line immunotherapy, immunotherapy combined with chemotherapy and LDH≤202.5 u/L were related to PFS (P < 0.05). Multivariate analysis showed that the patients with non-hepatic metastasis and LDH≤202.5 u/L had longer PFS (P < 0.05). The significant decrease of NLR and LDH after two cycles of immunotherapy indicated the effectiveness of immunotherapy (P < 0.05). Conclusion NLR≤2.81, LDH≤202.5 u/L, non-hepatic metastasis and immunotherapy combined chemotherapy are positively correlated with immunotherapy efficacy. Non-hepatic metastasis and LDH≤202.5 u/L are independent prognostic factors of the patients treated with immunotherapy. The changes of peripheral blood NLR and LDH are related to the efficacy of PD-1/PD-L1 inhibitors treatment.
